Abstract | OBJECTIVE: METHODS: RESULTS: ER expression was observed in 53.8% (28/52) of primary tumors and 48% (25/52) of metastases, while 57.7% (30/52) of primary tumors and 53.8% (28/52) of metastases showed ER mRNA positivity. There were variations in ER status between in situ hybridization and immunohistochemistry measurements and between primary tumors and metastases. Mutant p53 expression was inversely associated with ER-negative, high-grade tumors. CONCLUSIONS: In situ hybridization may be a more specific and sensitive method for determination of ER status than immunohistochemistry. It is possible that the biologic properties of ER change, and these changes may influence tumor response to endocrine therapy. In view of the ER variation, it was suggested that the ER status of metastatic tumors in addition to primary tumors should be taken into consideration in order to better determine the benefit of clinical endocrine therapy.
|
Authors | W Q Zheng, J Lu, J M Zheng, F X Hu, C R Ni |
Journal | Steroids
(Steroids)
Vol. 66
Issue 12
Pg. 905-10
(Dec 2001)
ISSN: 0039-128X [Print] United States |
PMID | 11711119
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- RNA, Messenger
- Receptors, Estrogen
|
Topics |
- Breast Neoplasms
(genetics, pathology)
- Female
- Gene Expression Regulation, Neoplastic
- Genes, p53
(genetics)
- Genetic Predisposition to Disease
- Humans
- Immunohistochemistry
- In Situ Hybridization
- Lymphatic Metastasis
(genetics)
- Middle Aged
- Mutation
(genetics)
- RNA, Messenger
(genetics, metabolism)
- Receptors, Estrogen
(genetics, metabolism)
|